Economic evaluation of first-line sugemalimab plus chemotherapy for metastatic non-small cell lung cancer in China.

ABSTRACT:

Objective

To evaluate the economics of sugemalimab plus chemotherapy in the first-line treatment of metastatic non-small cell lung cancer, and to provide a reference for the formulation of relevant medical insurance policies and rational drug use.

Methods

From the perspective of the Chinese health system, a three-state partitioned survival model was constructed based on data from a phase III randomized clinical trial (GEMSTONE 302) to evaluate the cost-utility of sugemalimab plus chemotherapy compared with chemotherapy in first-line treatment of metastatic non-small cell lung cancer. Model results were expressed as total cost, life years, quality-adjusted life years, and incremental cost-effectiveness ratio. The robustness of the underlying analysis results was verified usin

SUBMITTER: Wang H 

PROVIDER: S-EPMC9792693 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature